Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide

• Published in: European journal of clinical pharmacology 2015-05, Vol.71 (5), p.549-567
• Main Authors: Tamargo, Juan, Le Heuzey, Jean-Yves, Mabo, Phillipe
• Format: Article
• Language: English
• Subjects: Bioengineering; Biomedical and Life Sciences; Biomedicine; Cardiac arrhythmia; Dose-Response Relationship, Drug; Drugs, Generic - adverse effects; Drugs, Generic - pharmacokinetics; Drugs, Generic - pharmacology; Flecainide - adverse effects; Flecainide - pharmacokinetics; Flecainide - pharmacology; Generic drugs; Humans; Life Sciences; Pharmaceutical sciences; Pharmacology; Pharmacology/Toxicology; Practice Guidelines as Topic; Review; Review Article; Safety; Side effects; Therapeutic Equivalency
• ISSN: 0031-6970; 1432-1041; 1432-1041
• DOI: 10.1007/s00228-015-1832-0

Purpose The therapeutic index (TI) is the range of doses at which a medication is effective without unacceptable adverse events. Drugs with a narrow TI (NTIDs) have a narrow window between their effective doses and those at which they produce adverse toxic effects. Generic drugs may be substituted for brand-name drugs provided that they meet the recommended bioequivalence (BE) limits. However, an appropriate range of BE for NTIDs is essential to define due to the potential for ineffectiveness or adverse events. Flecainide is an antiarrhythmic agent that has the potential to be considered an NTID. This review aims to evaluate the literature surrounding guidelines on generic substitution for NTIDs and to evaluate the evidence for flecainide to be considered an NTID. Methods A review of recommendations from various regulatory authorities regarding BE and NTIDs, and publications regarding the NTID characteristics of flecainide, was carried out. Results Regulatory authorities generally recommend reduced BE limits for NTIDs. Some, but not all, regulatory authorities specify flecainide as an NTID. The literature review demonstrated that flecainide displays NTID characteristics including a steep drug dose–response relationship for safety and efficacy, a need for therapeutic drug monitoring of pharmacokinetic (PK) or pharmacodynamics measures and intra-subject variability in its PK properties. Conclusions There is much evidence for flecainide to be considered an NTID based on both preclinical and clinical data. A clear understanding of the potential of proarrhythmic effects or lack of efficacy, careful patient selection and regular monitoring are essential for the safe and rational administration of flecainide.